abelacimab
Jump to navigation
Jump to search
Indications
* much lower safety risk vs rivaroxaban[1]
Dosage
- 90 mg or 150 mg once monthly by subcutaneous injection
Adverse effects
- major gastrointestinal bleeding 0.5%[1]
- drug adverse effects of anticoagulants
- drug adverse effects of antithrombotic agent(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
Notes
- impact on prevention of stroke unclear[1]
More general terms
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 Lou N Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib. Phase IIb trial strongly favors safety of novel agent over DOAC, but stroke impact still unclear. MedPage Today January 23, 2025 https://www.medpagetoday.com/cardiology/arrhythmias/113911
ruff ct, patel sm, giugliano rp et al Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation N Engl J Med 2025;392:361-371 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39842011 https://www.nejm.org/doi/full/10.1056/NEJMoa2406674